The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.
Elias Dakwar, Frances R. Levin, Richard W Foltin, Edward V. Nunes, Carl L. Hart
Biological Psychiatry September 12, 2013 DOI: 10.1016/j.biopsych.2013.08.009 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized crossover double-blind trial Peer reviewed |
|---|---|
| Sample size | 8 |
| Population | Volunteers with active DSM-IV cocaine dependence not seeking treatment or abstinence |
| Interventions | Ketamine Lorazepam |
| Dose | .41 mg/kg or .71 mg/kg ketamine; lorazepam 2 mg |
| Duration | 52-minute intravenous infusions separated by 48 hours; assessments at baseline and 24 hours postinfusion |
| Measures | University of Rhode Island Change Assessment, visual analogue scale craving ratings |
| Topics | Addiction Ketamine Esketamine |
| Keywords | Humans Cocaine-related disorders Lorazepam Hypnotics and sedatives Infusions, intravenous Cross-over studies Double-blind method Behavior, addictive Motivation Cues Dose-response relationship, drug Middle aged Female Young adult Craving Glutamate |
| Key findings | Compared with the active control lorazepam, a single .41 mg/kg ketamine infusion produced a mean 3.9-point gain on the University of Rhode Island Change Assessment (about a 60% increase over preceding values) and a comparable reduction in cue-induced craving; a later .71 mg/kg infusion led to further reductions in cue-induced craving. The authors describe these as promising preliminary effects requiring further research. |
Abstract
Background: Cocaine dependence involves problematic neuroadaptations that might be responsive to modulation of glutamatergic circuits. This investigation examined the effects of subanesthetic ketamine infusions on motivation for quitting cocaine and on cue-induced craving in cocaine-dependent participants, 24 hours postinfusion.
Methods: Eight volunteers with active DSM-IV cocaine dependence not seeking treatment or abstinence were entered into this crossover, double-blind trial. Three 52-min intravenous infusions were administered: ketamine (.41 mg/kg or .71 mg/kg) or lorazepam 2 mg, counterbalanced into three orderings in which ketamine .41 mg/kg always preceded the .71 mg/kg dose. Infusions were separated by 48 hours, and assessments occurred at baseline and at 24 hours postinfusion. Outcomes were change between postinfusion and preinfusion values for: 1) motivation to quit cocaine scores with the University of Rhode Island Change Assessment; and 2) sums of visual analogue scale craving ratings administered during cue exposure.
Results: Compared with the active control lorazepam, a single ketamine infusion (.41 mg/kg) led to a mean 3.9-point gain in University of Rhode Island Change Assessment (p = .012), which corresponds to an approximately 60% increase over preceding values. There was a reduction of comparable magnitude in cue-induced craving (p = .012). A subsequent ketamine infusion (.71 mg/kg) led to further reductions in cue-induced craving compared with the control. Infusions were well-tolerated.
Conclusions: Subanesthetic ketamine demonstrated promising effects on motivation to quit cocaine and on cue-induced craving, 24 hours postinfusion. Research is needed to expand on these preliminary results and to evaluate the efficacy of this intervention in clinical settings.
Comparable studies
Other randomized controlled trials on ketamine for addiction, most cited first.
Citations in the library
Cited by 81
- Ketamine and Rapid-Acting Antidepressants: A Window into a New Neurobiology for Mood Disorder Therapeutics Annual Review of Medicine October 23, 2014
- Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years Therapeutic Advances in Psychopharmacology March 18, 2016
- Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development Frontiers in Pharmacology July 5, 2018
- Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms Pharmacological Reviews December 16, 2020
- KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID‐ACTING ANTIDEPRESSANTS Depression and Anxiety April 6, 2016
and 76 more in the library
Cites 11
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Science August 19, 2010
- Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex Journal of Neuroscience April 15, 1997
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Ketamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research Journal of Psychoactive Drugs June 1, 1997
and 6 more in the library